DSDaria S. Salygina

Daria S. Salygina

*This is an algorithmically generated author record based on publicly available information.

Daria S. Salygina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative evaluation of the efficacy of semi-elemental and polymeric nutritional formulas in combination with serotonin for the correction of nutritional status disorders and gastrointestinal insufficiency in the postoperative period in oncological patients: results of a pilot study

    by I.S. Simutis, D.G. Eremich, K. Blitsõn, D.S. Salygina, M.S. Danilov, A.A. Sapegin, L.B. Gaikovaya

    Objective. To improve perioperative outcomes in patients with malignant GIT tumors and pre-existing NI through early use of a semi-elemental therapeutic formula in combination with continuous infusion of serotonin adipinate. Material and methods. This was a prospective, randomized, single-center pilot study including 44 patients aged >65 years after elective GIT surgery for malignant neoplasms with documented NI (≥2 points on NRS-2002) and GII (≥3 points on the LIFE scale). All patients received a low-rate intravenous infusion of serotonin adipinate (20 mg/day) until resolution of GII. Early enteral nutritional support was initiated simultaneously: in the main group, a semi-elemental whey protein hydrolysate-based formula (Peptamen Intense) was used; in the control group, a standard polymeric formula (Nutricomp Intensive) was administered. The severity of GII was assessed using the LIFE scale; plasma serotonin levels, amino acid profile (methionine, arginine, valine, citrulline, etc.), laboratory markers of nutritional status and their dynamics were evaluated on postoperative days 1, 2, and 5. Results. In both groups, serotonin supplementation led to a rapid normalization of initially reduced plasma serotonin levels (from 49.8 ng/mL [19; 71.2] to values within the reference range already by postoperative day 1, with subsequent stabilization). In the main group, the semi-elemental formula provided a more pronounced nutritional effect: by day 5 there was a significant restoration (p<0.05) of initially decreased methionine, arginine, and valine concentrations compared with the control group. A less pronounced catabolic trend was observed for citrulline, a marker of functional enterocyte mass, along with a more favorable course of GII according to the LIFE scale (p<0.05) in the main group. Significant negative correlations were identified between GII severity and arginine levels (r=–0.994; 95% CI [–0.9968; –0.9890], p=0.01) and citrulline levels (r=–0.614; 95% CI [–0.819; –0.271], p=0.04), indicating active utilization of these amino acids in reparative processes under combined therapy. Conclusion. The results of this pilot study demonstrate the potential of early use of a semi-elemental enteral formula on the background of prokinetic therapy with serotonin adipinate to optimize postoperative restoration of GIT function and correction of malnutrition in oncologic patients with pre-existing NI and GII. The data obtained indicate a more favorable dynamics of the amino acid profile (methionine, arginine, valine, citrulline) and a trend toward less severe GII on the LIFE scale compared with a standard polymeric formula. However, given the small sample size and short follow-up period, these findings require confirmation in larger multicenter studies.


  • Open Access

    Serotonin as a means of preventing gastrointestinal failure in the early postoperative period: a randomized clinical study

    by Daria G. Eremich, Ionas S. Simutis, Mark S. Danilov, Daria S. Salygina, Kristina Blitsyn

    BACKGROUND: In patients with gastrointestinal cancers, preoperative malnutrition is associated with decreased plasma serotonin levels and an increased risk of gastrointestinal failure in the postoperative period. AIM: The work aimed to evaluate the safety and clinical efficacy of serotonin compared with standard prokinetic therapy for the correction of gastrointestinal failure in patients with malnutrition. METHODS: It was a randomized pilot clinical study including 42 patients aged ≥ 65 years after elective gastrointestinal surgery for cancer. All participants had malnutrition (NRS 2002 ≥ 2) and gastrointestinal failure (LIFE ≥ 2). Patients were randomized as follows: the main group (n = 24) received serotonin at a dose of 20 mg/day intravenously until gastrointestinal failure is resolved; the control group (n = 18) received standard therapy (metoclopramide, 10 mg, and neostigmine methyl sulfate, 0.1 mg, three times daily). Both groups received standardized enteral nutritional support with a semi-elemental formula. Changes in LIFE scores, plasma serotonin and albumin levels, inflammatory markers, hemostasis parameters (piezoelectric thromboelastography), and the incidence of thrombotic complications were assessed. Thromboprophylaxis was performed with enoxaparin sodium, 40 mg/day, administered subcutaneously. RESULTS: Baseline characteristics of the groups did not differ significantly. Serotonin levels were decreased in both groups (50.37 ng/mL in the control group; 51.6 ng/mL in the main group; p = 0.782). During serotonin administration, its concentration was maintained within the reference range, whereas in the control group it continued to decrease by day 2. By day 5, the severity of gastrointestinal failure according to the LIFE scale was significantly lower in the main group (0.3 vs 2.6 points; p = 0.045), which was accompanied by earlier recovery of peristalsis and bowel movements. A strong negative correlation was found between serotonin levels and the severity of gastrointestinal failure (rs = −0.69; p = 0.012). In patients receiving serotonin, hypoalbuminemia was corrected more rapidly (p = 0.0057); albumin levels also negatively correlated with the severity of gastrointestinal failure (rs = −0.71; p = 0.010). Inflammatory markers and hemostasis parameters did not differ between the groups. Thrombotic events were not observed in either group. CONCLUSION: In patients with gastrointestinal cancers and preoperative malnutrition, serotonin as part of complex therapy for gastrointestinal failure was associated with faster resolution and correction of hypoalbuminemia without signs of increased inflammatory response or an increased risk of thrombotic events.

  • Serotonin and intestinal insufficiency in the perioperative period

    by D. G. Eremich, I. S. Simutis, M. S. Danilov, D. S. Salygina, V. A. Ratnikov

    The review is devoted to the problem of postoperative intestinal insufficiency: one of the probable pathophysiological bases of this condition, serotonin deficiency, is considered. The problems of intestinal insufficiency from the point of view of functional and structural disorders of the intestine are considered in detail, the relationship of this condition with the synthesis and metabolism of serotonin is analyzed. Special attention is paid to the accumulated clinical experience in the treatment of intestinal insufficiency through the donation of parenteral serotonin preparations, the advantages and side effects of such therapy, as well as possible complications, are considered in detail. In this regard, emphasis is placed on the most rational and effective approaches to the correction of serotonin deficiency in the treatment of functional intestinal insufficiency of the perioperative period.

  • Advisability of NSAID combined with central muscle relaxant for pain syndrome after thoracoscopic surgery

    by M.S. Danilov, I.S. Simutis, D.S. Salygina, E.G. Polovtsev, A.A. Syrovatskiy, A.A. Bogatikov, M.E. Fedorov

    Objective. To compare the effectiveness and safety of diclofenac combined with orphenadrine and ketoprofen for postoperative analgesia after elective thoracoscopic surgery. Material and methods. A single-center randomized prospective study included 47 patients divided into 2 groups depending on postoperative analgesia regimen: group 1 (n=25) — Neodolpasse 75 mg (counted for diclofenac) intravenously immediately after surgery and 12 hours later; group 2 (n=22) — ketoprofen 100 mg. Effectiveness of anesthesia was assessed considering VAS scores, the need for opioid analgesics and laboratory criteria (cortisol). Safety implied analysis of serum cystatin C, azotemia, reticulocytosis, platelet count, INR, fibrinogen and D-dimer. Intraoperative anesthesia implied fentanyl 0.1—0.2 mg intravenously. The last injection (0.1 mg) was performed 15—25 min before the end of surgery. The Chi-square test and t-test were used for statistical analysis. Results. Postoperative VAS scores were similar at the first three points (after 3, 6 and 9 hours) (p=0.37, p=0.72 and p=0.23, respectively). There were no between-group differences in serum cortisol (348.24±0.34 and 402.22±0.44 nmol/l, p=0.48) and the need for narcotic analgesics (74.29±30.81 and 57.33±33.69 mg/day, respectively, p=0.084). At the same time, safety profile was comparable. We found no significant differences in hemostasis parameters (platelet count, INR, fibrinogen and D-dimer). However, Neodolpasse was potentially safer regarding the risk of renal dysfunction. Indeed, serum cystatin C after 24-hour treatment was lower in the main group (0.88±0.34 and 1.19±0.44 mg/l, respectively, p=0.031). Conclusion. Neodolpasse is effective for pain relief in various clinical situations including surgery. However, we found no significant differences between this drug and ketoprofen after thoracoscopic interventions. Safety profile of diclofenac combined with orphenadrine was better regarding the risk of kidney damage.


  • Open Access

    Experience in the use of non-immunogenic recombinant staphylokinase in the treatment of massive pulmonary embolism

    by N. Yu. Semigolovskii, I. S. Simutis, D. S. Salygina, M. S. Danilov, A. V. Svetlikov, S. N. Semigolovskii

    The actuality of the problem of pulmonary embolism is due to the widespread occurrence of this complication with unpredictable consequences, including hemodynamic instability, arterial hypotension, shock, disability and sudden death. Pulmonary embolism is now considered in developed countries as the most common cause of preventable inhospital death and maternal mortality. Thrombolytic therapy is used for intermediate and high-risk pulmonary embolism with hemodynamic instability of the patient, however, there is also ongoing discussion about the possibilities of its implementation in normotensive patients under certain conditions. Currently, streptokinase, urokinase and alteplase (Actilize and Revelise in Russia) are used for thrombolytic therapy of pulmonary embolism. Indications for use in pulmonary embolism have been expanded recently for the already wellknown domestic thrombolytic non-immunogenic staphylokinase (Fortelizin®), which has proven itself in patients with acute myocardial infarction and acute ischemic stroke. A clinical case of delayed (on the 4th day of hospitalization) use of Fortelisin with a positive effect in a 49-year-old normotensive anemized patient with syncope in the PE debut with non-occlusive thrombosis of the posterior tibial veins without flotation of blood clots is presented. The features of Fortelizin, which favorably distinguish it from other thrombolytic agents, are: the highest fibrin selectivity; the possibility of bolus administration of a fixed dosage, independent of the patient’s body weight; safety of repeated administration; high rate of onset of effect; prevention of a significant decrease in blood fibrinogen levels, which reduces the risk of bleeding. Thus, the use of the domestic thrombolytic recombinant non-immunogenic staphylokinase drug Fortelizin, taking into account the data of the conducted studies and the described case, seems to be a successful example of import substitution in medicine.

  • Can we make a safer sedation?

    by M.S. Danilov, I.S. Simutis, A.S. Korotaev, D.S. Salygina, V.A. Ratnikov, V.A. Kashchenko

    ЦЕЛЬ ИССЛЕДОВАНИЯ Повышение безопасности лечения пациента в ОРИТ с помощью BIS-мониторинга. МАТЕРИАЛ И МЕТОДЫ 69 пациентов ОРИТ, которые требовали проведения продленной седации, были разделены на две группы: в 1-й группе (n=38) седацию у пациентов контролировали непрерывно по уровню BIS, а для сравнения оценок использовали шкалу RASS; во 2-й группе (n=31) оценку проводили только по RASS. Для обработки результатов использовали t-критерий Стьюдента и коэффициенты ранговой корреляции Спирмена и корреляции Кенделла. РЕЗУЛЬТАТЫ В группе BIS-мониторинга средний расход пропофола составил 2696±300 мг/сут, а в группе оценки по RASS — 3205±360 мг/сут, то есть применение BIS-мониторинга позволяет снизить расход пропофола на 15,9% (t-тест –6,40, ppp<0,01). В 1-й группе не было нежелательных событий, связанных с угнетением сознания, а во 2-й группе два пациента переведены на ИВЛ из-за чрезмерно глубокой седации. Кроме того, авторы отмечают, что в ночное время контроль седации по RASS невозможен. ЗАКЛЮЧЕНИЕ Непрерывный мониторинг позволяет оптимизировать седацию и повысить ее безопасность. Кроме того, имеет место и экономическая эффективность непрерывной оценки уровня угнетения сознания.